Mesothelioma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

General requirements (all participants in the higher-risk group must meet these):

• Adults aged 18 or older
• Able to understand and read spoken and written French
• Willing to follow the study requirements and attend follow-up
• Able to use the internet via a phone or computer
• Willing to read, sign, and date a consent form before any study procedures begin
• People with a past cancer or blood cancer diagnosis may be eligible if they have been in full remission for at least 5 years

People in one of the following higher-risk situations may also be eligible:

Breast cancer risk:

• Women aged 40 or older with certain inherited gene changes (in BRCA1, BRCA2, TP53, PALB2, PTEN, or CDH1) who have not had preventive breast removal surgery
• Men aged 40 or older with an inherited gene change in BRCA2
• Women aged 50 or older with a personal history of an abnormal (atypical) breast tissue finding in the past 5 years
• Women aged 60 or older with a personal history of breast cancer (including early-stage ductal carcinoma in situ) diagnosed more than 5 years ago
• Women who received chest radiation therapy before age 30, and are now aged 25 or older
• Women aged 50 or older whose calculated 5-year breast cancer risk is greater than 2.5%, based on risk scoring tools with or without genetic testing
• People aged 50 or older who were identified as higher risk in the MyPeBS trial (with a 5-year risk above 2.5%)

Gynaecological cancer risk:

• Women aged 30 or older with Lynch syndrome (inherited changes in hMLH1, MSH2, hMLH6, or PMS2 genes)
• Women aged 40 or older with inherited gene changes in BRCA1, BRCA2, PALB2, RAD51C, RAD51D, or PTEN, who have not had preventive ovary removal surgery
• Women aged 30 or older with inherited gene changes in POLE or POLD1
• Women aged 18 or older with inherited gene changes in SMARCA4 or DICER1

Colorectal (bowel) cancer risk:

• Men or women aged 40 or older with Lynch syndrome or certain inherited gene changes (in hMLH1, MSH2, hMLH6, PMS2, APC, POLE, POLD1, BMPR1A, SMAD4, or both copies of MuTYH)
• People aged 50 or older with a close family member (parent, sibling, or child) diagnosed with bowel cancer before age 60
• People aged 50 or older with two or more close family members diagnosed with bowel cancer at any age
• People aged 50 or older with a personal history of bowel polyps found before age 50, or certain types of larger or more complex polyps found after age 50
• People aged 50 or older with Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis)

Upper digestive tract cancer risk:

• People aged 30 or older with inherited gene changes in STK11 or CDH1
• People with Barrett's oesophagus with high-grade changes in the cells (confirm with trial site)

Liver cancer risk:

• People with confirmed liver scarring (fibrosis) or cirrhosis, caused by fatty liver disease, alcohol, or a viral infection

Pancreatic cancer risk:

• People aged 50 or older with more than two close relatives who had pancreatic cancer
• People aged 50 or older with chronic pancreatitis, or those with inherited gene changes in PRSS1 or SPINK1
• People whose risk of pancreatic cancer is assessed as elevated using a combined scoring method (confirm with trial site)
• Carriers of an inherited gene change in CDKN2A
• Carriers of inherited gene changes in BRCA2, ATM, BRCA1, PALB2, or Lynch syndrome-related genes, with at least one close family member who has had pancreatic cancer
• People with Peutz-Jeghers syndrome (inherited STK11 gene changes)

Lung cancer risk:

• Current or former smokers aged 50 or older with a history of heavy smoking (more than 20 pack-years), who stopped smoking no more than 10 years ago (confirm with trial site for pack-year calculation)

Skin cancer risk (excluding common basal cell skin cancers):

• People aged 50 or older with inherited gene changes in CDKN2A, CDK4, or BAP1
• Carriers of inherited gene changes that increase skin cancer risk, such as those associated with Xeroderma pigmentosum

Head and neck cancer risk:

• People aged 50 or older with high-grade abnormal cell changes or very early-stage cancer in the upper airways or mouth, found within the last 10 years
• People aged 50 or older diagnosed with oral lichen planus more than 10 years ago
• People aged 50 or older with a previous head and neck cancer who have been in full remission for 5 or more years, and who are also a current or former smoker (more than 10 pack-years) or a current or former regular alcohol drinker (more than 14 units per week)

Mesothelioma risk:

• People aged 50 or older with a documented history of significant workplace asbestos exposure, and/or an inherited gene change in BAP1

Kidney cancer risk:

• People aged 50 or older with inherited gene changes in BAP1, VHL, FH, cMET, FLCN, or SDH-B

Prostate cancer risk:

• Men aged 40 or older with a strong family history, such as a close relative with advanced prostate cancer, ovarian cancer, male breast cancer, female breast cancer diagnosed at or before 45, bowel or womb cancer diagnosed at or before 50, pancreatic cancer, or two or more close relatives with breast, prostate, bowel, or womb cancer at any age
• Men aged 45 or older with inherited gene changes in BRCA1, BRCA2, ATM, HOXB13, hMLH1, MSH2, hMLH6, or PMS2

Bladder and urinary tract cancer risk:

• Current or former smokers aged 50 or older with a history of very heavy smoking (more than 30 pack-years), who stopped smoking no more than 10 years ago
• People aged 40 or older with Lynch syndrome (inherited changes in hMLH1, MSH2, hMLH6, or PMS2)

Endocrine (hormonal gland) cancer risk:

• People aged 35 or older with inherited gene changes in RET, VHL, SDHB, or SDHD, which are linked to a higher risk of certain adrenal gland tumours
• People aged 40 or older with Multiple Endocrine Neoplasia syndrome, linked to inherited gene changes in RET or MEN1

Blood cancer risk:

• People aged 50 or older with a condition called clonal haematopoiesis of indeterminate potential (CHIP) (confirm with trial site)
• People aged 50 or older with aplastic anaemia
• People aged 50 or older with certain inherited gene changes (in GATA2, RUNX1, ANKRD26, ETV6, TP53, CEBPA, or DDX41) or a specific chromosomal change (CNVdup14)
• People aged 50 or older who received high doses of platinum-based chemotherapy or similar treatments, and whose estimated 3-year risk of a secondary blood cancer is greater than 2%

Multiple cancer type risk:

• People aged 18 or older with Li-Fraumeni syndrome (inherited TP53 gene changes)
• People aged 30 or older with Cowden syndrome or related conditions (inherited PTEN gene changes)
• People aged 50 or older who had an organ transplant at least 5 years ago and are still taking long-term immune-suppressing medications
• People aged 50 or older living with chronic HIV infection

Childhood cancer survivors:

• People aged 18 or older who received brain radiation therapy during childhood
• People aged 40 or older who were treated with chemotherapy and/or radiation therapy for a childhood cancer

Other situations:

• People aged 50 or older with a significant work-related exposure that is estimated to carry at least a 2% risk of a specific cancer over 3 years
• People in any other situation where several combined risk factors are estimated to result in at least a 2% risk of a specific cancer over 3 years (confirm with trial site)

Control group (comparison group — separate eligibility):

• Adults aged 18 or older who attended a rapid diagnostic assessment at the trial centre (as part of the Instadiag programme) and received a result showing a non-cancerous (benign) condition
• People who do not fall into any of the higher-risk categories listed above
• Willing to take part, follow the study requirements, and sign a consent form
• Able to understand and read spoken and written French
• Able to use the internet via a phone or computer

Who may not be able to join:

• People who have been diagnosed with cancer or a blood cancer in the past 5 years (exceptions may apply for certain non-melanoma skin cancers, early cervical cancers, and people with an inherited TP53 gene change — confirm with trial site)
• People who currently have signs or symptoms that may suggest cancer
• People experiencing a flare-up of an autoimmune condition that required a change in treatment within the 14 days before joining
• People with a medical condition that is likely to result in death within three years
• People whose physical or psychological health may make it too difficult to take part in or follow the study requirements
• People who are under legal guardianship, have had their freedom restricted by a court or official decision, or are unable to give their own consent
• Women with inherited gene changes in BRCA1, BRCA2, or PALB2 who are planning preventive breast removal surgery in the near future, or who are under 40 years old (as their estimated cancer risk may fall below the threshold for this study)
• People who received a blood transfusion within one week before joining the study

Important: Always verify eligibility with the trial site directly before applying.